公司公告显示，已完成《公司章程》备案及工商变更登记手续，并取得浙江省市场监督管理局换发的 《营业执照》。 风险提示：股市有风险，投资需谨慎。 圣达生物股价报18.78元，较前一交易日上涨1.62%，成交额0.68亿元。 圣达生物主营业务为生物素、叶酸等维生素类产品的研发、生产和销售，产品广泛应用于饲料、食品、 医药等领域。公司所属板块包括化学制品、浙江板块、合成生物等。 ...

Group 1: Chemical and Oil Indices Performance - The chemical index and oil index showed overall positive performance, with the chemical raw materials index rising by 1.66% and the chemical machinery index increasing by 6.08%. However, the chemical pharmaceuticals index fell by 1.30% [1] - In the oil sector, the oil processing index increased by 0.67%, the oil extraction index rose by 2.70%, and the oil trading index went up by 2.18% [1] Group 2: International Oil Prices - International crude oil prices declined, with WTI settling at $63.88 per barrel, down 5.12% from August 1, and Brent settling at $66.597 per barrel, down 4.42% [1] Group 3: Petrochemical Products Price Changes - The top five petrochemical products with price increases included liquid chlorine up by 14.98%, coke up by 4.57%, mancozeb up by 4%, coking coal up by 3.55%, and aniline up by 2.82%. The top five products with price decreases included folic acid down by 6%, acrylic acid down by 5.51%, vitamin D3 down by 5.41%, WTI down by 5.12%, and synthetic ammonia down by 4.90% [1] Group 4: Capital Market Performance of Chemical Companies - The top five chemical companies with the highest stock price increases were Kexin New Energy up by 53.05%, Amway Co. up by 51.60%, Xinhang New Materials up by 45.88%, Zhongxin Fluorine Materials up by 35.66%, and Huaxin New Materials up by 25.99%. The top five companies with the largest declines were Lianhua Technology down by 10.41%, Cangzhou Dahua down by 8.80%, Zaiseng Technology down by 8.63%, Yabeng Chemical down by 7.86%, and Xinchao Energy down by 7.21% [2]

Investment Rating - The report maintains a positive outlook on the chemical industry, suggesting to focus on chemical products with significant market potential [4][5]. Core Insights - The chemical sector experienced a 2.33% increase in the first week of August, outperforming the Shanghai Composite Index by 0.22 percentage points [12]. - The top five performing stocks in the sector included Anli Co. (+51.6%) and *ST Jintai (+19.18%) [12]. - The report highlights the significant price increase of formic acid (+28.62%) and other chemicals, indicating strong market dynamics [3][21]. Industry Performance - The chemical industry had 29 sub-industries rising and 3 declining in the first week of August, with potassium fertilizer leading the gains at +11.61% [2][17]. - The dynamic PE ratio for the chemical sector is reported at 27.11 times, slightly below the average PE since 2015 [12]. Price and Spread Trends - The report lists the top five products with the highest price increases, including formic acid (+28.62%) and dichloromethane (+17.5%) [3][21]. - The price spread for PX (naphtha-based) saw a significant increase of +36.66%, while PTA spread decreased by -52.14% [39][42]. Inventory Changes - Notable inventory changes include an increase in polyester filament (+14.71%) and epoxy propane (+12.92%) [60][62]. Recommendations - The report recommends focusing on companies with strong performance, such as Xinyangfeng and Guangxin Materials, which are expected to benefit from ongoing market trends [4].

Group 1: Chemical Industry Performance - The chemical raw materials index increased by 4.45%, the chemical machinery index rose by 2.16%, the chemical pharmaceuticals index grew by 0.94%, and the pesticide and fertilizer index surged by 5.43% during the week of July 21 to 25 [1] - The oil processing index increased by 3.53%, while the oil extraction index decreased by 1.86%, and the oil trading index rose by 1.20% [1] Group 2: Oil Price Trends - As of July 25, the WTI crude oil futures settled at $65.16 per barrel, down 3.24% from July 18, while Brent crude oil futures settled at $68.44 per barrel, down 1.21% from July 18 [1] Group 3: Petrochemical Product Price Changes - The top five petrochemical products with price increases were Vitamin D3 (up 12.12%), battery-grade lithium carbonate (up 11.62%), organic silicon DMC (up 11.61%), raw rubber (up 9.76%), and 107 glue (up 8.33%) [1] - The top five petrochemical products with price decreases were Atrazine (down 14.73%), methyl acrylate (down 9.47%), hydrochloric acid (down 6.32%), cracked carbon nine (down 5.84%), and folic acid (down 5.66%) [1] Group 4: Capital Market Performance of Chemical Companies - The top five performing listed chemical companies were Shangwei New Materials (up 97.37%), Yokogawa Precision (up 64.42%), Poly United (up 52.73%), Gaozheng Mining Explosives (up 39.83%), and Subote (up 31.83%) [2] - The bottom five performing listed chemical companies were Pioneer New Materials (down 11.67%), Dazhongnan (down 9.90%), Qide New Materials (down 9.61%), Yueyang Xingchang (down 9.38%), and Qingdao Jinwang (down 8.50%) [2]

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The prices of the main products, Vitamin B1 and B6, remain strong, contributing to profit growth. The company is a significant supplier in the global B vitamin market, holding leading market shares in Vitamin B6 and B1, with a revenue contribution of 78% from B vitamins in 2024. The prices for Vitamin B6 and B1 have shown year-on-year increases of 43.8% and 21.04% respectively in the first half of 2025, driving rapid profit growth [8][5] - The company is expanding its product line with new projects, including Vitamin B5 and Vitamin A, which are expected to enhance its long-term growth potential. The successful launch of these new products could significantly increase the company's market presence [8] - The financial forecast has been slightly adjusted, with expected net profits for 2025, 2026, and 2027 projected at 921 million, 1,063 million, and 1,070 million respectively. The corresponding PE ratios are estimated at 13, 11, and 11 times. The target market value for 2025 is set at 141 billion, indicating a 21% upside potential from the current market value [8][10] Financial Data and Profit Forecast - Total revenue is projected to grow from 2,209 million in 2024 to 2,708 million in 2025, with a year-on-year growth rate of 22.6%. The net profit is expected to increase from 651 million in 2024 to 921 million in 2025, reflecting a growth rate of 41.4% [7][12] - The gross margin is anticipated to improve from 42% in 2024 to 51.1% in 2025, while the return on equity (ROE) is expected to rise from 14.1% to 16.6% during the same period [7][12]

Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]

Vitamin Sector - The vitamin sector is expected to benefit from price increases in 2024 and Q1 2025, with revenue projected to grow by 22.5% and net profit by 162.6% year-on-year in 2024 [1] - In Q1 2025, revenue and net profit are anticipated to continue their upward trend, with increases of 10.8% and 110.3% year-on-year, respectively [1] - The demand for feed-grade vitamins remains rigid, and certain concentrated supply structures are expected to support price increases for products like Vitamin E, D3, and folic acid [1] Fine Chemicals Sector - The fine chemicals sector is projected to outperform the basic chemicals sector in 2024 and Q1 2025, with a decline of only 4.2% in 2024 compared to a 5.1% drop in basic chemicals [2] - By the end of Q1 2025, the fine chemicals index is expected to rebound to 6905.55 points, reflecting an 8.5% increase year-to-date, surpassing basic chemicals by 2.4 percentage points [2] - The fine chemicals industry benefits from relatively inelastic downstream demand and high production barriers, making it more resilient during downturns and more elastic during recoveries [2] Amino Acids Sector - The amino acids sector is forecasted to see revenue growth of 8.9% and net profit growth of 55.0% in 2024, driven by recovering demand and lower raw material costs [3] - In Q1 2025, the sector is expected to continue benefiting from lower corn prices and increased export demand, with revenue and net profit projected to rise by 9.0% and 74.6% year-on-year, respectively [3] - Notably, methionine prices are anticipated to rise due to low channel inventory and market expectations, presenting potential opportunities for price increases [3] Pesticides Sector - The pesticides sector is showing signs of a cyclical rebound from 2024 to Q1 2025, despite an overall oversupply in 2024 leading to a revenue decline of 2.3% and a net profit drop of 73% [4] - In Q1 2025, certain pesticide products are expected to experience rapid price increases due to temporary supply-demand imbalances, resulting in a revenue increase of 4.5% and a net profit increase of 57.2% year-on-year [4] - Future price increases may be driven by strong demand for specific crops and supply constraints due to uncontrollable factors [4] Sweeteners Sector - The sweeteners sector is projected to show resilience in revenue with a 2.1% increase in 2024, although net profit is expected to decline by 32.5% due to price drops in core products [5] - In Q1 2025, revenue is anticipated to grow by 7.1% and net profit by 81.1%, benefiting from price increases initiated in late 2024 and ongoing demand for functional sugars [5] - The sector may see further price increases for sucralose and potential growth opportunities following the approval of natural sweetener allulose in the domestic market [5]